Harmonization of molecular monitoring of CML therapy in Europe (Q37587749)

21 August 2017

1 reference

title

Harmonization of molecular monitoring of CML therapy in Europe (English)

1 reference

21 August 2017

G Saglio

9

0 references

Andreas Hochhaus

object named as

A Hochhaus

10

0 references

author name string

M C Müller

1

1 reference

21 August 2017

N C P Cross

2

1 reference

21 August 2017

P Erben

3

1 reference

21 August 2017

T Schenk

4

1 reference

21 August 2017

B Hanfstein

5

1 reference

21 August 2017

T Ernst

6

1 reference

21 August 2017

R Hehlmann

7

1 reference

21 August 2017

S Branford

8

1 reference

21 August 2017

27 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

23

1 reference

21 August 2017

1957-1963

1 reference

21 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.168

21 August 2017

0 references

cites work

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Statistical methods for assessing agreement between two methods of clinical measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Measuring agreement in method comparison studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

inferred from DOI database lookup

7 January 2021

based on heuristic

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.168

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.168

1 reference

21 August 2017

1 reference